Fig. 6

EV-encapsulated miR-101 attenuates PE by repressing BRD4 expression via inhibition of NF-κB/CXCL11 axis. a Blood pressure observed at the 15th, 17th, and 19th day in PE modeled rats, healthy rats and sham-operated rats. b 24 h urine protein observed at the 15th, 17th and 19th day in PE modeled rats, healthy rats and sham-operated rats. c Overexpression efficiency of miR-101 in HUCMSCs and HUCMSC-derived EVs determined using RT-qPCR. d Blood pressure observed at the 15th, 17th and 19th day in PE modeled rats, healthy rats, sham-operated rats, PE modeled rats treated with NC-EV, or miR-101-EV. e 24 h urine protein observed at the 15th, 17th, and 19th day in PE modeled rats, healthy rats, sham-operated rats, PE modeled rats treated with NC-EV, or miR-101-EV. f–h The weight of fetus and placenta in PE modeled rats, healthy rats, sham-operated rats, PE modeled rats treated with NC-EV, or miR-101-EV. i Placenta stained by HE staining in PE modeled rats, healthy rats, sham-operated rats, PE modeled rats treated with NC-EV, or miR-101-EV (scale bar = 25 μm). j Expression of miR-101 in PE modeled rats, healthy rats, sham-operated rats, PE modeled rats treated with NC-EV, or miR-101-EV determined by RT-qPCR. k Expression of BRD4, NF-KB, CXCL11, IL-6, TNF-α and p65 and IkBα in PE modeled rats, healthy rats, sham-operated rats, PE modeled rats treated with NC-EV, or miR-101-EV determined by immunoblotting. *p < 0.05